P.2.c.027 Healthcare cost associated with first-line antidepressant treatments in severe depression in the United Kingdom - European Neuropsychopharmacologydoi:10.1016/S0924-977X(08)70473-5A. G. WadeD. SaragoussiN. DespiégelF. Guelfucci...
outperform sunitinib: nivolumab plus ipilimumab (CheckMate 214) and lenvatinib plus pembrolizumab (CLEAR). Of three studies that reported no difference from sunitinib, two suffered design flaws that might have obscured HRQoL benefits (JAVELIN Renal 101 and KEYNOTE-426). To ensure future HRQoL data a...
RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced it has initiated a Phase 3 clinical trial evaluating MK-1084, an investigatio...
Eribulin therapy may contribute to its clinical benefits [19, 21] by rendering residual tumors less aggressive and less likely to metas- tasis through an EMT-reversal effect [20]. Furthermore, Kashiwagi et al. reported that eribulin suppressed the expression of EMT and hypoxia markers ABC ...
4,10 A number of these triplets have been approved by the European Medicines Agency (EMA) in recent years (i.e., IsaKd; DKd; DPomd) and offer improved survival benefits in Len-refractory patients, thought their use was limited in our study (received in <2% of patients) due to the ...
The benefits of combination and switching did not, however, persist after continuation treatment at the treating physician’s discretion at week 25. Combination or switching strategies resulted in 6–8% fewer patients continuing the allocated treatments up to week 9 than continuing on sertraline. ...
There are currently several recommended drug regimens for uncomplicated falciparum malaria in Africa. Each has different properties that determine its impact on disease burden. Two major antimalarial policy options are artemether–lumefantrine (AL) and d
In patients who have CD4+ cell counts greater than 350 cells/mm³, the benefits and risks of therapy -- including comorbidities, patient readiness, adherence issues, drug-drug interactions and other factors -- should be discussed with them before making the decision regarding whether to treat ...
Packer M. Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new standard of care. Eur Heart J. 2020;41(25):2393–6. Article PubMed PubMed Central Google Scholar Papazafiropoulou AK, Meli...
Classifying breast cancer based on molecular subtypes is a growing clinical practice that warrants benefits [2,20,21] and it is primarily conducted in the West [22,23]. There is limited information on this practice in the Asian population [24]. Breast cancer incidence in the Asian population ...